Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Wave's DMD drug remains on track in 48-week data
As it prepares to submit an approval application next year, Wave has presented fresh phase 2 data showing its DMD drug is up to the task.
James Waldron
Mar 26, 2025 9:50am
Avidity's latest DMD data drop assuages safety concerns: analyst
Mar 17, 2025 2:00pm
PepGen pauses UK arm of DMD trial that's already on hold in US
Mar 4, 2025 10:25am
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Feb 24, 2025 11:08am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Cumberland's DMD drug improves blood flow from heart in ph. 2
Feb 4, 2025 10:20am
